Suppr超能文献

β2 - 肾上腺素能受体的药物遗传学:与哮喘的相关性

The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma.

作者信息

Liggett S B

机构信息

Departments of Medicine and Molecular Genetics, University of Cincinnati College of Medicine, Ohio, USA.

出版信息

J Allergy Clin Immunol. 2000 Feb;105(2 Pt 2):S487-92. doi: 10.1016/s0091-6749(00)90048-4.

Abstract

The beta(2)-adrenergic receptor (beta(2)AR) is the molecular target for beta-agonists used in the treatment of asthma. In the human population, 4 polymorphisms of the beta(2)AR coding block have been found, 3 of which result in receptors that have different properties compared with wild-type. To date, clinical studies suggest that these beta(2)AR polymorphisms may alter asthmatic phenotype and the response to beta-agonist therapy, making these variants the first of undoubtedly several genetic loci that will ultimately be found that will provide for individualized therapy in asthma.

摘要

β₂肾上腺素能受体(β₂AR)是用于治疗哮喘的β激动剂的分子靶点。在人类群体中,已发现β₂AR编码区有4种多态性,其中3种导致产生的受体与野生型相比具有不同特性。迄今为止,临床研究表明,这些β₂AR多态性可能会改变哮喘表型以及对β激动剂治疗的反应,这使得这些变异成为首批无疑将最终被发现的、可为哮喘个体化治疗提供依据的若干基因位点中的第一个。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验